Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SBT777101 · 2 trials · 2 indications
Death, CRS, ICANS, vital organ toxicity, hematological toxicity
| Arm | Type | Description |
|---|---|---|
| SBT777101 Dose Level 1 | EXPERIMENTAL | Low dose SBT777101 |
| SBT777101 Dose Level 2 | EXPERIMENTAL | Mid dose SBT777101 |
| SBT777101 Dose Level 3 | EXPERIMENTAL | High dose SBT777101 |
| Cohort 1 - SBT777101 Dose 1 | EXPERIMENTAL | Low dose SBT777101 |
| Cohort 2 - SBT777101 Dose 2 | EXPERIMENTAL | Mid dose SBT777101 |
| Cohort 3 - SBT777101 Dose 3 | EXPERIMENTAL | High dose SBT777101 |
| Cohort 4 - SBT777101 Split-Dose Administration | EXPERIMENTAL | Participants receive two intravenous infusions of SBT777101 derived from a single manufacturing process. Total administered dose ranges from approximately 300 million to 900 million CAR+ Treg cells, divided across two administrations. |
| Name | Type | Description |
|---|---|---|
| SBT777101 | BIOLOGICAL | Experimental treatment |
Inclusion Criteria: * Body mass index (BMI) ≤50 kg/m2, inclusive * Diagnosis of clinically active moderate-to-severe HS (Hurley Stage 2 or 3) * Total abscess or inflammatory nodule (AN) count of ≥5, affecting at least 2 distinct anatomic regions, with at least 1 accessible AN of adequate size for b...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Upadacitinib |
| Incyte Corporation | INCY | 6 | PHASE3 | Povorcitinib |
| Novartis AG Sponsored ADR | NVS | 11 | PHASE3 | Remibrutinib Dose A, Remibrutinib Dose B |
| MoonLake Immunotherapeutics Class A | MLTX | 2 | PHASE3 | Sonelokimab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | Brivekimig |
| Pfizer Inc. | PFE | 1 | PHASE2 | Ritlecitinib |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Zasocitinib |
| Zura Bio Limited Class A | ZURA | 1 | PHASE2 | Tibulizumab Dose A, Tibulizumab Dose B |
| Sonoma Pharmaceuticals, Inc. | SNOA | 2 | PHASE1 | SBT777101 |
| Evommune, Inc. | EVMN | 1 | EARLY_PHASE1 | EVO101 |
SBT777101 is an investigational monoclonal antibody being developed for rheumatoid arthritis and hidradenitis suppurativa. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being studied in adult patients with these conditions.
SBT777101 is being developed by Sonoma Pharmaceuticals, Inc., a biopharmaceutical company. The company is conducting Phase 1 clinical trials for this investigational drug in the United States.
SBT777101 is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. Two Phase 1 trials are ongoing, one in rheumatoid arthritis and one in hidradenitis suppurativa.
SBT777101 is being studied in two Phase 1 clinical trials. NCT06201416 is a single-dose study in subjects with rheumatoid arthritis, and NCT06361836 is a single-dose study in subjects with hidradenitis suppurativa. Both trials are being conducted in the United States.
SBT777101 is a distinct investigational monoclonal antibody. No alternative names have been reported for this drug. It is being studied specifically for rheumatoid arthritis and hidradenitis suppurativa.